Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population

Miniatura

Archivos

Pranita D. Tamma, Maria Virginia Villegas_2020.pdf (142.46 KB)

Fecha

2017

Autores

Título de la revista

Publicado en

Antimicrobial agents and chemotherapy, 1098-6596, Vol. 61, Nro. 8, 2017

Publicado por

American Society for Microbiology

URI

https://hdl.handle.net/20.500.12495/3503

URL de la fuente

https://aac.asm.org/content/61/8/e01094-17

Enlace a contenidos multimedia

ISSN de la revista

Título del volumen

Resumen

Descripción

Abstract

β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.

Palabras clave

Keywords

ESBLs, Bloodstream infection, Neutropenia

Temáticas

Beta-Lactamas
Inhibidores de beta-Lactamasas
Carbapenémicos

Citación

Colecciones

Artículos